U.S., April 1 -- ClinicalTrials.gov registry received information related to the study (NCT07502872) titled 'TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma' on March 14.
Brief Summary: This is a single-center, phase 2, open-label clinical trial of a novel combination of polatuzumab vedotin, glofitamab, and tafasitamab (TPG) as first-line treatment of patients with diffuse large B cell lymphoma (DLBCL) or high-grade B cell lymphoma (HGBL).
Study Start Date: May 01
Study Type: INTERVENTIONAL
Condition:
Diffuse Large B Cell Lymphoma
High-grade B-cell Lymphoma
Lymphoma
Lymphoma, B-Cell
Intervention:
DRUG: Tafasitamab
Cytolytic monoclonal antibo...